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Abstract 
The immune response consists of two main components: humoral immunity represented by B lymphocytes and cellular 
immunity maintained by the T lymphocytes. Immunoglobulins, produced by B-lymphocytes, are the main mediators of humoral 
immunity, and deficiencies at this level affect the body's response to infection. Plasmocytes produce nine antibody izotypes: 
immunoglobulins G (IgG 1, lgG2, lgG3, lgG4), immunoglobulins M (IgM), immunoglobulins A (lgA1, lgA2), immunoglobulins D (IGD) 
and immunoglobulins E (IgE). Primary hypogammaglobulinemias are characterized by the occurrence of recurrent infections and, 
paradoxically, by the occurrence of autoimmune diseases. Characteristic for these diseases is that symptoms occur at 7-9 months 
after birth, when transplacental antibody titers transmitted from the mother decrease, and the infant’s body is unable to synthesize 
them to normal levels. Primary hypogammaglobulinemias are transmitted genetically, but mutations at the molecular level are still not 
fully understood. The most common are: Bruton agammaglobulinemia , transient newborn hypogammaglobulinemia, selective 
immunoglobulin deficiency and variable  common immunodeficiency. Treatment consists of monthly antibiotics and immunoglobulins, 
depending on antibody titers (except for IgA deficiency). 
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Introduction d
Primary hypogammaglobulinemias are 
characterized by the occurrence of recurrent infections 
and, paradoxically, by the occurrence of autoimmune 
diseases. Characteristic for these diseases is that 
symptoms occur at 7-9 months after birth, when 
transplacental antibody titers transmitted from the mother 
decrease, and the infant’ body is unable to synthesize 
them to normal levels. Primary hypogammaglobulinemias 
are transmitted genetically, but mutations at the molecular 
level are still not fully understood. The most common are: 
Bruton agammaglobulinemia, transient newborn 
hypogammaglobulinemia, selective immunoglobulin 
deficiency and variable common immunodeficiency. 
Bruton agammaglobulinemia 
Pathophysiology  
 
Bruton agammaglobulinemia is a primary 
immunodeficiency caused by the existence of mutations in 
the gene that encodes Bruton tyrosine kinase (BTK) on 
chromosome X. Approximately one third of the mutations 
are at sites CGG, which encodes for arginine. This 
disorder was first described by Bruton in 1952 and is a 
defect in maturation of pre-B lymphocytes in mature B 
lymphocytes. Thus, plasmocytes are absent and 
reticuloendhotelial tissue and lymphoid organs (tonsils, 
spleen, Peyer plaques, lymphnodes) are poorly 
developed. Immunoglobulin titers are more reduced or 
absent. The disease occurs with a frequency of 
approximately 1:250.000 males. Females are only carriers 
and show no clinical symptoms. The disease signs occur 
when transplacental IgG antibodies, transmitted from the 
mother, decrease and due to the plasmocytes’ absence 
cannot synthesize other immunoglobulins.  
 
Clinical signs  
First symptoms appear at less than 1-year of age, 
patients presenting recurrent otitis, sinusitis, pneumonia 
with encapsulated bacteria such as Streptococcus 
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pneumoniae, Haemophillus influenzae, Pseudomonas 
aeruginosa, Mycoplasma catarrhalis, Neisseria 
meningitidis, but also with cutaneous symptoms (impetigo, 
abscesses, furuncles) caused by group A streptococcus 
and Staphylococcus aureus. Patients with Bruton's 
disease are predisposed to enteroviral infections, 
meningitis, bacterial diarrhea (Campylobacter jejuni) and 
Giardia infections. In adult patients, obstructive and 
restrictive pulmonary impairment occurs as a complication 
of recurrent infections. The incidence of autoimmune 
diseases (thrombocytopenia, neutropenia, hemolytic 
anemia, rheumatoid arthritis) is, also, increased.   
 
Diagnosis  
IgG titers are low and a value below 100 mg/dl is 
suggestive for X-linked hypogammaglobulinemia. 
Confirmation is made by flowcytometry which determines 
B and T lymphocyte levels. Imagistic studies may suggest 
the presence of chronic sinus and lung infections and 
quantitative reduction of lymphoid tissue. Since they were 
discovered, 5 years ago, spirometry tests have been 
indicated.  
 
Treatment  
There is not a curative treatment. Therapeutic 
measures consist of intravenous immunoglobulins (400-
600 mg/kg monthly in order to maintain the IgG levels at 
500-800 mg/dl), specific treatment of bacterial infections 
with antibiotics and bronchodilators. Nutritional 
multivitamins supplement is also recommended.  
 
 
Prognosis and complications 
 The prognosis is well on a long time basis if the 
patients are diagnosed in due time and an appropriate 
therapy with i.v. immunoglobulins is applied, before the 
appearance of recurrent infectious sequelae. It is 
important that before surgery, patients with X-linked 
hypogammaglobulinemia should receive intravenous 
immunoglobulins. Immunization with living virus vaccine is 
contraindicated.  
Transient newborn 
hypogammaglobulinemia  
Pathophysiology  
At birth, the child is endowed with immunoglobulins 
from the mother. These are IgG, IgM and IgA levels which 
are very low. Any infection considerably increases the IgM 
level. Immunoglobulins from the mother are metabolized 
in about 3-5 months. Normally, up to 6 months of life, the 
child synthesizes about 33% of IgG levels, 30% of IgA and 
70% of IgM.  
IgG production begins only after 2 months of life and 
IgA and IgM production even later. Therefore, any delay or 
extent of physiological hypogammaglobulinemia between 
the 3rd and the 6th month of life, and of recovery period 
between 18 and 36  months defines transient newborn 
hypogammaglobulinemia and is self -limited. Actually, this 
is a delay of normal IgG synthesis, which normally 
resolves by itself until the 16th and the 30th month of life. 
Sometimes, an impairment of IgA or IgM levels is 
observed. Most cases are spontaneously solved before 3 
years old.  
 
Clinical signs 
Symptoms may be absent or sinopulmonary 
infections may exist, severe infections being rare.  
 
Treatment  
      Treatment consists of antibiotics and, in severe cases, 
a substitution therapy with immunoglobulins could be 
necessary.  
Disgammaglobulinemia or selective 
immunoglobulins deficiency 
Selective IgA deficiency 
       There are several immunological diseases associated 
with immunoglobulin deficiency, and the most common is 
selective IgA deficiency. IgA was first described by Graber 
and Williams in 1952, the first case of IgA deficiency being 
described 10 years later. The incidence of disease is 
approximately 1:2.000 individuals, and symptoms appear 
in 1:500-700 affected people. In this disorder, plasmocytes 
are unable to produce IgA, although B-lymphocytes level 
is normal. It seems that there is a lack of B lymphocyte 
response to interleukins - IL-4, IL-6, IL-7 or IL-10. This 
disorder may be associated with one or more 
immunoglobulin deficiencies, particularly of some IgG 
subclasses deficiency, and the lack of response to 
immunization with pneumococcal vaccine. Subsequently, 
some patients develop common variable 
hypogammaglobulinemia. The use of drugs such as D-
penicillamine, sulfasalazina, captopril, valproic acid, 
carbamazepine, ibuprofen, and exposure to certain 
infections (rubella, cytomegalovirus [CMV], toxoplasmosis) 
can cause reversible IgA deficiency. Seasonal variations 
of IgA antibodies was also described, these increasing in 
winter.  
 
Clinical signs 
        In  a  major  IgA  deficiency,  the  symptomatology  is 
represented by repetitive sinopulmonary infections, otitis, 
meningitis and pneumonia. Patients may also experience 
asthma, allergies and gastrointestinal and urinary 
infections. People with total IgA deficiency develop 
antibodies against IgA. In case of blood transfusions, 
these patients can develop anaphylactic shock reactions. 
In addition, there is a risk of autoimmune diseases such 
as autoimmune thrombocytopenia, rheumatoid arthritis, 
and lupus erythematosus.  
 
Diagnosis  
        Normal titers of IgA are of 100-400 mg/dl and, in a 
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patient with selective IgA immunodeficiency, they get less 
than 7 mg/dl. IgA serum which is less than 0.05 g/dl in at 
least 2 determinations, undetectable secretory IgA and 
exclusion of other primary and secondary 
immunodeficiencies focus on diagnosis. Imagistic and 
pulmonary functional tests help to determine various 
infections and complications.   
The treatment is the prevention of infections and proper 
administration of antibiotics.  
Selective IgG deficiency 
It can be classified depending on IgG subclasses 
deficiency: 60-70% is IgG1, 20-30% IgG2, 5-8% IgG3 and 
1-3% IgG4. IgG1 and IgG3 titers reach normal values at 5-
7 years old, while IgG2 and IgG4 grow slowly and reach 
these values at the age of 10 years old. IgG1 and IgG3 
are antibodies involved in antitoxins protection (diphtheria 
toxin, tetanus) and in antiviral protection. Instead, 
antipolysaccharide antibodies are predominantly IgG2. 
  
Clinical signs 
Most frequently, patients develop recurrent otitis, 
infection that may progress to deafness or total loss of 
hearing. Pulmonary infection may develop into an 
obstructive pattern. Most times, IgG deficiency (especially 
IgG2 and IgG4) is associated with IgA deficiency and 
these patients do not respond to immunization with 
polysaccharide vaccine against pneumococcal or H. 
influenzae. Moreover, the deficiency of these two 
subclasses of IgG associated with IgE deficiency meet in 
a disease called ataxia-teleangiectazie.  
 
Treatment  
The treatment consists of individualized antibiotics 
schemes up to well-documented bacteriological diagnosis, 
and, in some cases, immunoglobulins substitution is 
required. 
Selective IgM deficiency 
It is a very rare disease (less than 300 cases 
described in literature) and is defined by low levels of IgM 
- less than 20 mg/dl in children and less than 2 standard 
deviations relative to the adult corresponding values. 
Infectious agents in children are represented by 
Pneumocystis carinii, Giardia, S. aureus, Salmonella sp, 
N. meningitidis, CMV, Pseudomonas aeroginosa and 
Moluscum contagiosum. The agents that cause recurrent 
infections such as dermatitis, diarrhea, meningitis, 
respiratory infections, sepsis and even death characterize 
varicella zooster.  
Treatment consists of immunoglobulin 
administration.  
Common variable immunodeficiency 
Common variable immunodeficiency (CVID) is 
characterized by a low titer of immunoglobulin, leading to 
increased susceptibility to infection. In most patients, the 
diagnosis is established in the 2nd or 3rd decade of life, but 
recurrent infections are common since childhood. 
Incidence of this pathology is about 1:10.000 - 50.000, 
without predilection for a particular race and both sexes 
are equally affected. 
 
Pathophysiology  
The primary immunological defect lies in the inability 
of B-lymphocytes to differentiate into plasma cells, 
resulting in a low antibody titer. Genetic abnormalities 
underlying this disease are the shortage of CD 19 (with a 
role in regulating the B lymphocytes response to antigens) 
and mutations in certain genes that encode factors 
involved in the production of different antibody subclasses 
and in the production of IL-10, IL-2, IL-4, IL-5, IL-13 (with a 
role in the cooperation between B and T lymphocytes). 
Studies have demonstrated a low expression of CD40 
ligand in the activated CD4 T lymphocytes, resulting in low 
production of IL-2. Thus, patients with CVID present low 
levels of IgG and IgA and approximately 50% of patients 
present low levels of IgM. 
 
Clinical signs 
Most patients present chronic respiratory tract 
disorders: sinusitis, otitis, laryngitis, pneumonia. Due to 
the low IgG production, the most commonly pathogens 
involved are represented by encapsulated bacteria such 
as Strptococcus pneumoniae and H. influenzae. 
Moreover, patients may also present infectious diarrhea 
(Giardia lamblia, Salmonella, Shigella, Campylobacter) or 
diarrhea resulted from ulcerative colitis or Crohn's 
disease. Studies show an increased incidence of gastric 
adenocarcinoma, lymphoma, as well as benign 
lymphoproliferative disease (splenomegaly, diffuse 
lymphadenopathy). Approximately 20% of patients with 
CVID develop autoimmune diseases, such as 
autoimmune hemolytic anemia, autoimmune 
thrombocytopenic purpura, arthritis, thyroiditis.  
 
Diagnosis  
The diagnosis is both clinical and paraclinical, by 
emphasizing low IgA, IgG, IgM titers in the absence of 
other known causes of antibody deficiency. Measuring the 
levels of IL-2, IL-4, IL-5, IL-6, TNF is an alternative way of 
targeting the diagnosis, in a patient with recurrent 
infections. The most frequent diagnosis is made by 
excluding other immune deficiency problems, whose 
primary genetic causes are well known.  
 
Treatment  
Treatment consists of intravenous or subcutaneous 
immunoglobulin administration, every 2-4 weeks, in order 
to maintain the normal antibodies titers (400-500 mg/dl). 
Most patients respond well to therapy with 
immunoglobulins except for the patients with 
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gastrointestinal events. Corticosteroids or other 
immunosuppressants are necessary in the cases of 
patients with gastrointestinal events and those with severe 
autoimmune phenomena. Antibiotic therapy should be 
initiated at the first signs of infection, but long-term 
prophylaxis is contraindicated because of the risk of 
antibiotic resistance.  
Clinical conclusions  
Hypogammaglobulinemias are relatively rare, often 
associated with acute or chronic recurrent infections,  
 
resulting in a decreased quality of life and a decreased life 
expectancy.  
It is necessary to consider these diseases in advance 
whenever a child or adult presents a recurrent infection 
after proper antibiotics administration.   
Next, it is important to determine the causes that lead to 
insufficient production of different antibodies classes, to 
develop specific markers for diagnosis and to redefine 
treatment protocols in order to decrease the risk of 
complications.  
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